0001193125-21-326034.txt : 20211110 0001193125-21-326034.hdr.sgml : 20211110 20211110162100 ACCESSION NUMBER: 0001193125-21-326034 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20211109 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211110 DATE AS OF CHANGE: 20211110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oric Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001796280 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 471787157 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39269 FILM NUMBER: 211396975 BUSINESS ADDRESS: STREET 1: 240 E. GRAND AVE. STREET 2: 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 388-5600 MAIL ADDRESS: STREET 1: 240 E. GRAND AVE. STREET 2: 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 d241352d8k.htm 8-K 8-K
false 0001796280 0001796280 2021-11-09 2021-11-09

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

November 9, 2021

 

 

ORIC Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39269   47-1787157
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

240 E. Grand Ave, 2nd Floor
South San Francisco, CA 94080
(Address of principal executive offices, including zip code)

(650) 388-5600

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common stock, par value $0.0001 per share   ORIC   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Resignation of Director

On November 9, 2021, Carl Gordon, Ph.D., C.F.A. submitted his resignation as a director of ORIC Pharmaceuticals, Inc. (the “Company”). Dr. Gordon’s resignation was voluntary and did not result from any disagreement with the Company or the Company’s Board of Directors (the “Board”).

(d) Election of Director

On November 9, 2021, the Board appointed Angie You, Ph.D. to serve as a Class II director, with a term expiring at the Company’s 2022 annual meeting of stockholders, as well as serve as a member of the Company’s Audit Committee and Nominating and Corporate Governance Committee.

There are no arrangements or understandings between Dr. You and any other person pursuant to which Dr. You was selected as a director. In addition, there are no transactions in which Dr. You has an interest that would require disclosure under Item 404(a) of Regulation S-K.

Dr. You will receive compensation for her service pursuant to the Company’s non-employee director compensation policy as described in the Company’s proxy statement (File No. 001-39269). This includes an annual cash retainer of $35,000 per year for service as a non-employee director, $7,500 per year for service as an Audit Committee member and $4,000 per year for service as a Nominating and Corporate Governance Committee member. Additionally, as a new non-employee director, Dr. You was granted a stock option to purchase 33,250 shares of common stock upon her appointment to the Board. This stock option will vest as to 1/36th of the total number of shares on each monthly anniversary of Dr. You’s commencement of service as a non-employee director, subject to her continued service through the applicable vesting date. In the event of a change in control (as defined in the Company’s 2020 Equity Incentive Plan), the stock option will vest in full. In addition, Dr. You also executed the Company’s standard form of indemnification agreement.

A copy of the press release announcing Dr. You’s appointment as a director is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.

   

Description

99.1    Press release dated November 10, 2021.
104    Cover Page Interactive Data File (formatted as Inline XBRL).

 

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      ORIC PHARMACEUTICALS, INC.
Date: November 10, 2021     By:  

/s/ Dominic Piscitelli

     

Dominic Piscitelli

Chief Financial Officer

 

-3-

EX-99.1 2 d241352dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors

SOUTH SAN FRANCISCO and SAN DIEGO, CA – November 10, 2021 – ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Angie You, Ph.D., to its board of directors. Dr. You currently serves as chief executive officer of Amunix Pharmaceuticals, Inc.

“We are delighted to welcome Angie to ORIC’s board of directors,” said Jacob Chacko, M.D., president and chief executive officer. “Angie’s broad experience spanning venture capital, a variety of business development transactions, and public company leadership will bring valuable expertise and insight to ORIC as we continue to build and advance our pipeline of novel oncology candidates toward potential clinical proof of concept and commercialization.”

Dr. You joined Amunix Pharmaceuticals as chief executive officer of in 2018. Prior to joining Amunix, Dr. You served as chief business & strategy officer and head of commercial at Sierra Oncology (Nasdaq: SRRA), where she led the company’s strategic and transactional business and commercial efforts, including building its robust pipeline through acquisition and licensing of several product assets. Prior to Sierra Oncology, Dr. You served as chief business officer of Aragon Pharmaceuticals. In previous roles, Dr. You served as chief business officer at Synosia Therapeutics and Ren Pharmaceuticals. Before joining Ren Pharmaceuticals, Dr. You focused on new company formation at Venrock Ventures. Dr. You earned a Ph.D. in Biochemistry from Harvard University and a B.A. in Chemistry from Harvard College.

Dr. You added, “I have watched with interest as Jacob and the highly experienced ORIC leadership team have used both cutting-edge internal drug discovery and targeted business development to build an impressive pipeline of promising oncology candidates to treat a range of cancers. I am excited to join the board and look forward to working with the leadership team to support the next phase of growth and evolution of the company.”

Concurrent with the appointment of Dr. You, Carl L. Gordon, Ph.D., CFA, founding and managing partner at OrbiMed, resigned from ORIC’s board. Dr. Chacko stated, “I would like to thank Carl for his guidance, support, and partnership during his tenure on the ORIC board dating back to his initial investment in our Series B in 2015. On behalf of the entire ORIC Board and leadership team, we are incredibly grateful to Carl for his many contributions to ORIC that have positioned us well to achieve our mission of improving patients’ lives by overcoming resistance in cancer.”

LOGO

 

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials in combination with (1) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors and (2) Xtandi (enzalutamide) in metastatic prostate cancer. ORIC’s other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers. Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding development of the Company’s product candidates and statements by the company’s president and chief executive officer or board members. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC-101, ORIC-533, ORIC-944, ORIC-114 or any other product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of the COVID-19 pandemic on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license agreements; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market

LOGO

 

conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 8, 2021, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

###

Investor Contact:

Dominic Piscitelli, Chief Financial Officer

dominic.piscitelli@oricpharma.com

info@oricpharma.com

EX-101.SCH 3 oric-20211109.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 oric-20211109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 oric-20211109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g241352g1110092408844.jpg GRAPHIC begin 644 g241352g1110092408844.jpg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g241352g1110092409172.jpg GRAPHIC begin 644 g241352g1110092409172.jpg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d241352d8k_htm.xml IDEA: XBRL DOCUMENT 0001796280 2021-11-09 2021-11-09 false 0001796280 8-K 2021-11-09 ORIC Pharmaceuticals, Inc. DE 001-39269 47-1787157 240 E. Grand Ave 2nd Floor South San Francisco CA 94080 (650) 388-5600 false false false false Common stock, par value $0.0001 per share ORIC NASDAQ true true XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 09, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001796280
Document Type 8-K
Document Period End Date Nov. 09, 2021
Entity Registrant Name ORIC Pharmaceuticals, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39269
Entity Tax Identification Number 47-1787157
Entity Address, Address Line One 240 E. Grand Ave
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 388-5600
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol ORIC
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d241352d8k.htm d241352dex991.htm oric-20211109.xsd oric-20211109_lab.xml oric-20211109_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d241352d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d241352d8k.htm" ] }, "labelLink": { "local": [ "oric-20211109_lab.xml" ] }, "presentationLink": { "local": [ "oric-20211109_pre.xml" ] }, "schema": { "local": [ "oric-20211109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "oric", "nsuri": "http://www.oricpharma.com/20211109", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d241352d8k.htm", "contextRef": "duration_2021-11-09_to_2021-11-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d241352d8k.htm", "contextRef": "duration_2021-11-09_to_2021-11-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oricpharma.com//20211109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 16 0001193125-21-326034-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-326034-xbrl.zip M4$L#!!0 ( )R":E/*=5Q\@1$ (9J . 9#(T,3,U,F0X:RYH=&WM M76MSXCC6_KY5^Q]4S/164A6,#>0"N6PQA/10TYVD2*9VWO?+E+!%T+2Q/)(= M8'_]GB/98'.'D'1/3U+5'8SN1\^Y2\[%OT<#GSPSJ;@(+@N.91<("USA\>#I MLA!'O>)9@?S[ZI__N.A'4!$J!ZKN,7Y9Z$=16"^51EWI6XJYUI-X+D%!J6R7 M[:+M%"M.(:D>JV(T#IF:M.E1U;6$?"JE)0L:!2((XL&DR7 XM/10V,R+9 G; ME:!2$6HQR=VTW2B*[PQ?KSP^#-1T=AGEP6/J]"G8V0#5K@B M%WQ4QQ9,)I^YY[' ?(8JMX8'2$ 'V);Q>F/ @_^13<^?4KF,8HZK ?%L=1D M_AT!6W2T=E(^L^?G5YJAC&0])D&:,07/R,YUI9D.QB): M$M11BEP6%!^$/F)'?]>7.!5D[F+*TM9(>6DQE:X4N$4;"XY7$$E7%Z7\>I+5 MYU:LGY6(I7G4/%1/R*UW;P-RI\V8WKS)(_?PBQYGDN@IL(4OV*I(??X4U%U8"Y.%?/F0>U&_?F8=\^ \4]=GO>A\0.43#XKXN4YH M'(GT&\F?^LE7V%V8=H9RL]AGNA0T=CCI(A)A/?/8%5$D!OJ;KI P]?0;)QP1 M)7SND1]L_5.X^M>>!,MU6H1,ROP#2@ZTI*OY?5G?. M)L\].N#^N/[(!TR16S8D'3&@P;DN&YIY=X7OG2_8GE]OVX^M:_+PV'AL/2R? MCOU&TWEH-7_MM!_;K0?2N+TFK=^:/S=N/[9(\^[SY_;#0_ON]D5S+.]CCO^A MJ@]V822"(W)M-2U2MH^KM9EY30>M;0#,/![6,=1"8)[L!$S+AFIY;)X;)BT[ M'^87OR&33A>3RHA%^U5[(TS=W'4^+S<1KH4;HX60L50V5\/:"LKKWW<O[X]#! )KW/3H> T58 M4+BZ%<]LT 6KM79$L-V[#'M]&5:N[@,XR_68\2L[[(DKC"-$MU"RM3Z[Z[2; MY%X'9_QW;B['] KI@C(AV?49):U4/V T(?)F M2I^9U%R04->L>&'-I)_R%OVDJ]-G M 0C9BG*%F7%)!DTD!Z>Z!A*960N F8(^QSDL)-AWA7ZSD@M$#!"@G+6XNDA M HW5%'$0R7%3>"_2?AAUQ=!(Q$(IGG%85'_7S*=#T(3S:@]7L04,4M#/U?\* M-+SA/H,RT.H[!!.=8J56/JE]5P1YI*-V$F)S-05VI$[UM.BKR/,: MW'GV-LQYH#D._0X1]<$H_ .L?>5Q[9!<="4IH2/ LRQZ^&T#XZ I!@.NU&3^ MR!O$;/^W/O5VYX&T!J$OQDR:R>=!3&Z%=3@'//@/->[?6('7:G\#/=GP/,F4 M2GY] JO2V5JR M!AZP1 S0O?&%D&\MI[\M=#3AXYU\%,-@ZVUY$''4)P\PAQN A\N5*W:%A]8I M=_(>S"ZN,]);3J796)=X73+PO0![S_]_'NYB.U[5JO9\2O5[T?,)A=!9#B7L M"@^I3]B(N>#I/Z,/#4J&@;\/17Z,0I[\EX= 08]MI'&VB_SM)02P%!+(! W8 MDIU <'!R;!]N#K]/ O;AOB^"7>WORME9\?C$7H"[W4,L>\F<'$S#2?_ZX:SL MG)XK *;/0EPL"?1JLW !GXJF>'E!4'@OT+@5$6F$H0], CC]^J2\ :\4C&L3 MK9+:285':E@2B-@C)K0.(@ %)O&I2D/6[S&KU\@IK4,9Z* ^<[\0\(D(#4,I M0&:BG]05(])EOACBGF$A[BS)R=YAGT>LB)8S WX>2AHFJ4(M1$F/^\@M7 'K M1"SP8,\C =L^B/V(!DS$RA\3!5)#]<9ZA*2!Z *YC!<@S-"9F&<,_0">@G%: MU@,K7 RQ'<8^.'I#BAPHQLA'%C )HK\=0-O8))X:5MDRRSJL+X5;=6=/8J^> MPL0]F+H,\[[)C.^RF5<-F (P-+O4"314P7!=JY&4ZXS^21[#UZ*C&0>+: MJ1='NKI"^%T*VQX!2''.M=-J]7Q>K:QS??7<,P@@^4TG+Q;@,V=_"E<)/8 M68*0,),B[<2 HVKY.$%ZE,],8D+RP#DES9L.*5=L"RH>&B&QD8_\CNQ](?L! MY+T+>Q(\?09I"2+3_QO#>DH,Z-I08Q[3:U6'4Z5%IYQJCRG\<]GX%/QK>RM7 M;86@V"/>'S,G-=T^<7VJU(1K7SDWNRL1OS;%)$7F-9GAA_$ ZAVHPW>B MK0X%)R<$- MD1O38WEXU^"6*H_^23[Z DQJL)=\L)C(9RJ_L&AM5O8-3+QVX*'5RTAW3%R= M'8 >OX (8?KDU$Q(GBL"E ;+&0=](D]2#*,^&L\AANFI(A[K\< <43;13?LX M-0AG0IOFKD6%'" 63L]UA#.MS/7AYA /-V-F:4,+O-PM3D)*\V,NNNBQOM-T M=FB-S_6?F:;UJNG!PE5K"5S,5B)(D>RQ_CX$,.0^-V M!# _*)'LF2MH![R ATZ [ZGKXOE?K(PO-/"H])3)8GDK/:K* 9UX5%D$6VMW M?O0XF;2Y>O-UMCUO^&R7V?W>[D6;]&Z2Y/WG/T#Q+>(.APWFN ._REAJ709[ M Y::/Z1C53 W5_!]%A.K#MQ=(>L_U/3/>;J@<)2+>I7T:RKT/%;GT/=[WQU? MB/%6EVQ 3$1L8';@V+++Y)J!?1?%4EO/UUP"LPFID&>;8%A04%MW^LR05.>D MY2=7&+-5S_$(AN!!A-$C+)EOAV*6!8I"]3%I2(D\B[75HNK6BFM')_N0DQB2 MZ3 %FT1G%[/#T'K+0;;"H15+4RLPB0V91XZ3)@29$#E)UXV*=LGR<:4#\YYX<6 MN996,OCD.%!VG"$,]"Q\D-P4]A+/EWK9P,]9, /9!'8G:VNG@ZU^6[96Z5OQ@IWN%"S+\M3+)2Y8]81;PW MSB'',/,$/D@N0T9J^!+0T@B>."/_)^($4/HL"I//S."FB5$9TTV[/4'14:+% M8>YR *H_Y%(? (L6[AP,7H9]#V+0[6#K:\4.)-,^9!\$#W#V$8XV9+ZO+^]- MAQ\8!DB4^FS'C=CC$=''_0'Y3&/N5@PX A*G X_-Y-H" ^2".X0F!INV6(F3 M\AOM%S@^(&+!909>@5]9$2A-:%Q;0; B1;HL&H*WA*QH-@4V3J]3,X[V0L#H M4FA[9F7$Y"6" )\&":MH8T9J:ST[8==4W+.D83$6Q- M!)?$R]=1'U Q%+'O@1CX,X9!D/U=7RA4+";R/]4[5;N:&'%KO8T.>XI].C7_ M'HJ_6*G'\0WL:I[:') -Y&5XT-9-51Z*#K2-<=<0\Z#C%2A>$XU/N&\7^L'!^!;:@C2WB#79,L)9=&[HMH M MT*M# 6"$,1&A1@9@#W (#A3X=I7*4?G8-C$];92YF0@@B4/XB/BE&4,O@:[6 M-);9Z%SWFAN>43C %*"R4ZJ<1'TSLT321R("+)@CQEI7),,')HJKWVC@HY$1 M<'QM(QHQ'B(-QDDZDL1/_73 M4Z3)<62]>$0$OIU!RUOM03\G,Z3)66#D1NQ2"I\BQ03"] MN#8Q^+X)G=L PH:3L[*AOAU#=.53EW-LAUR,PFS/*3B7&G)E$QS)R?K19Z.-J63 MP6?'GGGSRJNFP7^ZZURW.L7FW:=/C?N'5CW]L/=[C!A%2'+AR0?/Q+'3ITVR MUJ>KLM8U^XVSUAMGG(FN<%E8<.5@HQ,O&^0@2?K:4/-NU6+7![&W]ZQB@EB# M-S!T=DG"+LWL[)3 WSO]-/<4D5M>1#U\XP+:EUKOY-.K4TY8P/#S*$OOHV#) M JIEBD&\(\L#T,IO?"]X/N>V<-]0&;P67$R>CQ+S#E>O7'4JQV6/C6HUQ^I' M WVP*Z/OT CQ9D(&CFUB!J@,Z%("_ETVR[&KK[I7370%R#VL$&PPD"[H88/I M=DTC2K2G=6#2"XFOWM9RC>!+H]&?FC+3) 6Z*FP\)Q3(G&Q?]W;2?42?%XC4 M8KE($LV-:YG&_[60>$\"O$428.%;6=L?;QN/OW9:#V]LNN=?DFARD3J$-,D0 M;)"W/EJ4Q/1B\!Y=&BOMSNB N7YY( S3!4<)5@\%PKPZK,OZU.]A;A0[,@$Y M4P%M_#B -KH[V*R^D+ P;\Z$_B[,V(6&Z\P![N/4[MS&E%UY +.Z58^K3G+N M?VK'.2M[WIAY(YVUSMCN]GX]'!$VK=- M:\V;'C8Q=Y"_5]D[NGS>X'FMNE_/D#+O9:TOL2O_BK#Z:5Q_O7.B_B7/U/U!+ P04 " "<@FI3/S>G;D'E^.7F_\^7C^'JT0U^(=@OCABIUR@[ZI^-?Q-7UK^>C]SL+ M';KYX=ON:YWN"!GK*'V_$ZN9X[?ZGZIAB;213G>=R0[W,G=G8&/Z33/#NB67#PA\YQ_[V-G9'9 M\/[XIP_B:C)\OQ/M'_1>O=Z/>KW>WMZ[_8.]MV\/#KJ_91&]>/U^Y_SRPZ4W MW?KV&^OR_K^5 0/V*%OPBD]S:1,9J,+I0,:Y.,XRHU.'/])(*_&K*3H8 MTSWM=H0S0N.+$R-M*,Q,G&JK F=L7IO_ <-]TP/\5N1.SY9\@JO+S]"Q^>-9[O71^SO[??* M+VCS8ILM.F*\Z @I@EBG-$+D3D:JW3)I8&(3+45@DDRF M2YPC*'(%(Z4B5+!KS762 -%U@_E$J=+38'/(8T3TCN+YJ17'W39M')96+FL*TYMUR,>XT50 M6(M)XJ7(E;V%W64N@KE6,Z'N5("]W"J\/M,!S$<+)46J[]JM[0;[SD@>P&T' M;XZ^X/A6P;XQ!1X9Q(B%BN$"51H"#\AE-/S'HVU&Z-!7;X]$+G4H_B$#,Q7# MN0QN3$?\Q.;+R $A69=0Q09IM^Y9I"O\CGC5>C5K9 CK9)',A("0:W MF*_ S@.9:2=C M2MQ""WI,U-BURGA(H2..Q;9V6:R\!ID\+(M)>LF,8 2 6X M6,E0V7RN,['0<8S5>249%W(:*[\-IW/%[^HT)Y-5]B%?+[ =F%RG!9MM6N@X MY+$RO"7X"5/8=BO3&:R=TL%%BFB*Q0KY&*Q#Z> I9Q9DZ,PX;%TC2NIPR:S! MF_B'M0*5E58U2:)L@('Z#TDG[)9>^=XP6@N WQ!'P) ']B81M%N/AX-.P2>] MMUWQR6ICR8 T'7G S]=9#S8.L7 58I7+_8@?9)(!DG"Y4]&R7H9,-8>7O?DJ MDPG0R)56UDIQ6;FBYJNKR>08?+4 H0!^H(NXI(T2-154R[4 )UJD@349MULU M'M=])=1L9JP#&G4:Q$5(AV74T!]$.=;@32=JR+BY-44T%S+XO="YINEY2J!8 M 8]X"P?+@7GK@1(6 ?"1Y\KE#;MNG/6)AEVC+BLC++WAX2Z8BZ+]5IL"[K8F M5OE_.CFY8IF:7$MQO>)P;[B)VK+DB8()58V5+6,VMM!(*REPO,HV>,<;U(E? M5&I-<$/_)Y;9)'HE+>%<^@1!R#W1)IBK!'G&+MNMF36)^"CM+87PYQ1 MW#6 MTG.!..D>\SO#Z@6Q-GYHXEA%ZKMG@'M28.V(2*LJ[)2@"JM-Z'#P14EJ^TTOV)>H1-*/CDQ39-V$1FP/(?+5NKU M(@.N0A1'_$9 _$T)?RRP<747Z#)9$NZ(#A#CG!DY&HVY(3PQ@U-"-?:&%F.[ M.::0=4-@3%Y A5C'7Z?J#C$_ESDO'5FSP'LTL;HU<<$8]1*G F^3[/]2]3B$ M_;SH61UN0TXU404A*6TLSKOB@[&A26N%-3P[[F#E(F7FHZ-B.1G1ATQ:EWIB MN+13_1.AD@1%1!%(@=-NW=,GC7#U4H0TIFOB>6&*F&CSAC,UA&1ZX_<&MP&_ MN8@*H($E8^F94C'XW;#KPH+U 8U&DB8Q8A@*'NP>#D 4DSHV00O16/ 4)W2= M0B)Z,P%"D ;BBL(%I4&9"E]W0=%BJN8RGE4.)S%@_0KMULD*<>N ZI 4(5V' MM&)5J*>(QHC2TZR(:1MK)TV(_4BW6#UE<.6UIF&!S5&:&9]M8/."A$[,\T@B M\5O6-0(!E9?(I*@SM]YY3I-4]]Z!O4D53Y&/$[4TX8AS)>R&5.16/_XT1< MC?^%>'FU4TW)E?SALW?\WX[X,CZ]_OA^!\7GW^H@&(XNKD>3/U_F/U;H?^\" M.7OJNJ))$&\W"_SOUZF@NO1X:@KW6$WYE8+YQ^_!>%O+?4319CTKIMID:\-J MI8'$BL]E_OAZK/3'@_[GP67_Y6<<%G^/!W7P4&SP$PR8- :L0FKU_;CQ?=IX M/FP\]\%7?8?_>605F)& A:3?FT* : 96 M2JB9ZI25:;O%2?9Y[X7WR_'4RCL)2?/533Q/Y7073V+4RGA>D$S-=X&0#CCUGQ^#T>& M['P?2'E9"55G:K<>.U5E"+;QZU>O:FQ!^AF40+ PPE#>2AUS!;\!+)UR\]-P M23,\??.*N@@W:HFR/.1LQ'(F5%2.P,H(T#ER!I 54]9C6&4QM9,$]0.IY**2 MAUY<1QM5!L;C:KGKFP<)2MKZT522!JX;6ZB<4$?B+_#<5!$UE/*6! ]YJ0)O MLL331#XA^&KGL:7>'1PT+06;P%O0'L&Z1>CTF8F7A$"<;L/"2ZBF.?M7G_AB2Y)A7/T0FO M>C.3G"?T5E7H;EQN-5]M598-=-@V(7A5\"2/*^Y<^9C;?W-H^9Q5*0< M!YR->^]>O?*%__H[O=&6=T9W!#1HH]7+!]VF]9AR[QW&M_D!*#"FR%!G(98P MRA%ZJ'EGU2/'Q/P%%,$C=B@3#I"7F#I^K5MJR_(RX;L8'/(+ZNDSRZ=L$0V0 M2TO-(LXO5'[ZRI46*34R&010?]3-U_/'8%!%A*+^KU6D>["(3[Q%!I9I:I-2 MG]$E!9W?$52RI\00K?WPAP M16XLW9QT*0H*T@PJ!Y'3#JDE$>K9K#%+7#8'W=SD1/3F-[SJ@[1L6CYTX-!? M0J1%HJP!DUJ=W_A#T,V7)6-04*ZWGAW%6+L5PRF^/CFLWLMS$V@N6NI&#W83 M^-9MW9_#+)UFBMJ\FN#HL464KX(ZES-_H:)P<*__22H4=,V2BWD!RMO0Y!B+ M7&M]9T72 VK(PE(;%5@96D=KOI53'5,KUM6IM%-V9!S=0=I2W3B?55<3PD)E M#-'ID'FSNF2.SL>,M$S\T MH]=PU1T2;6IS^]C.$Q38O>KM:75/4Y,_[8VF-GUB;=4[J%Y@FR\?KBW(A#Z^ M?..PX>(*!?P'Q5["%Y<4"2P!#%.4#[XR8H\0\9%DQ***ER#**N=]=>/#RU_& MI[N]=]7&@=-0)1#@&TQ4XIREYBI.-USHO4QQ6JUO D]A 3>0R22*[DL[)< 8 MY]Y(@;9!D52E"L6DIZ&(3F7IKI/;HXI50EF&TIQK+0&^? *X(ZL\^3P8LBEE ) MRW:K\75>%7:?4^8XEA]Y*3N1&2(JN0OJAJJ-/L+VX>-5G$+=\4UIS'&:$PE3>$O^NAF MFA.-\S*,0QW6(HQO9X78>.JF>C@F*:]&J0I!^?7_WNZ?[NV^Z[W9_Q_N M[=XK8-HMX,/30>Y5H2J<)L M7L8'X=W15;Z7IA-BSS/)/V@IU>E&$OZY0+ KDAD3Q3=UF 2%8/*4[-G;V_VY MHOJ9CILBJE$>T1GJ$@GU1'6C\IS&^6U>C89^=R]H^>JW6-YM;_WOL7P%W=SY MK.!?REC>=E[JT,UMC(8LH?-'133IM42&K,RJ5BQ1BO^P6;BM=N+U,HZ8$ILA M5+PSL9,BX_?=H^*](_SO%AJ#$>TYB>_%'*GD$1W]D'C^VH+JSO^TA@[S>Z$M M738O12P7W;_LDK7ZC>&S9\^^^Z]X^B>#,5]'PM!#JI0"=_BU7L8WN>8YI7L, M)(9/*" TI33=$4.N>L^@-E+^D7T> M4,]L8U5*DI\'#Z=+N.GR]%<\Y!\M_QM02P,$% @ G()J4TV1Y.I, P M@0L !$ !OGK5R=OXAC.SB^N((:%<[7- M&;N]O4W*F5!6R\:1!9L4NF(0QYW^W]=?X5MK/8<)2N06H>+6H8$/C9!E/D@' M67H\R))!'V:0>WM0D,<\L:&2G%I(5&%%$/^O^X M>QC*A)?8-7#&[32 .HD/3QJG67R4]7":S&PY\QOU@IN*AU3Y\&19.NI!2A1K M1*!FL4CF^H:1X&$G7DL\?*1!FAXQJ@]'4<<>1 KUXP#"BZ=4*GTG]R"W1P&0 MC48C%J0[E$JW?8Z5]2%KA4';/]PY(Z:-PW-MJC.<\482LE'_-5R*F< R:%+M M5JCU%L3>F:6%!>% M'VW9VW89^^43,K7!OS17OV"HSX37M="S?1JBS9] MB>==G4]P!F'$Y=P41DL\/ A9;72-Q@FZ%C:MTAI8&)R-(]TFN)U"WR6?)C2% M.I5[#K:;SXL905!>;NAU6">\W[FX];&WSJ M<0EB:?J'M.T_]>>>UI,/[_UNPK\ KC4/ W80]'KEAMA^WVNU2UC4R MV^WDU4Z_X]NM=N+0ZT]02P,$% @ G()J4R(]+U.Q!@ .TH !4 !O MX>6\VH/)3T XUFA:9 MDPS!TB1(W&W8,!2RQ-C$9-(@Y=C^]B/UT,@Q)5/1L/.ELC.IX^O M7WWXP?/@]/SB"CR8Q_%2CGJ]]7K=#>\IDSQ:Q4I2=@.^Z('GY?'CR1?X(RTW M@EL2$5\26/@R)@)^7=$H' W[PT'_W7#0'1;3!/&U'H1^3$8P&/0&_9Z.A%]& M;]^-WKZ%F\]PEL@PF- %*>;RY5;0V3R&GX*?(4DZY8R1*");.*?,9P'U([C+ M6WX#%RSHPDD4P:U.DZI/2<0#";N9:D39?R/]UU1W#Z]? :C3R&2R[[BC3T9V M+C93$76YF*E>^T>]/*7SF+'92UD?)0F#]^_?]Y*CQ6A)3;%*?-#[Z_/E73 G M"]]3IU]]N8*LC*0CF>R_Y$%R#BT:A-((_3\O#_/T+F\P](X&W8T,.Q]UP>SL M^%,27:HM2#R,!(](16%].*G>R>+C[5+%DTU,6$@RY6_:/,BBYH+'K#ZP^R/G]4N[Z.N:+^9"ICX0?Q;M5(GR@N\IV)E>.. M(:FWVY:..Q'!CI8O@EQ';1XX"UE$+^#JJ[>,O40Q3[\7?&'L(BO'#0>_1M/( MV*;F26WI(2?,^W)WR&LJ5#0FB.0KH2"K\P5._'Q,E.&?7/O?#[W'VB^E574A MD>2R;K\88)XL%/+J3WP>^3-;,)\DM02FN75N.-@$3(,0$IC?E$%+-\;20:-% M+&V[Q8#RC,4TWHY5,>%'%^J2O/F=;&WA+$EN"=)J*[PBJ FT%8)(\*85("L! M20U011IC[+#U(L[U^\< ^Y0'*SU#$^7!EN?=G)8P-C;.]X\U@79?!XG57!BT M-IML(K@C" -0ABDYN6 %4# M=!$TB!VT;J39NG^\Y<,MF5&]A&;QE;^PYMJ&N'!XK M@"Z!M&YPT;=AV6#=/![.%RS@8LE%3 M6Z=S)V"D(247(2H*NB30JW\&787*>;PYOE,YI1*Y6BRD1]>:FF-?J MD!@,)O+D*UB*+W-+VE_AQV2T5: M!?F0-6X1W!SQ2F%(8?O,$X"4-E0V;_7%)&!O6&PBC0 MZD!46>(' IL/0JDH[A!D^F_R#="5X)IAK6R@$HOZ ,P5IO78L+7[%GX%]-? OP&.R;T'\/0 MP'\JZ0A[70:X %T(%WEL U7 V[E ASWYF?E:W C^0%E0\]9/F<9+P+[,F(G] M)[%H V#4=30%Z#7<4G%BIFH<:?M"'XH;+V(_^ILOZ=T/-"B]A(,RF M3..P$XDV# 951Z.05@)5"O,.ISL;56-@[07EQW<]KZ5*&I<;Y_ MK-%G"O=TD/!-OO-K91Q:\?O<^3RA9;,8..H/_48W<\YJWE_?SVL)RU(#W'R\ M"9YF+21$$W%(U+'N,+KIMXAJG:8Q-%X&NVST&U'<\H@&-*9M]5NMQ0?W(EFA39DLX M5YC@91%-0"Y30Z+X41YR_<8(NVJYR&^MOC'@O1%$SPI1<"2?L=3OXXCK^WO[ MI4250DLP6YCBAR*;P'U(%0ER50:*=2 M!$FEQKB[-E'$_IE.' S A90K(IJ/ M@4'G90Q#N4'S2.S%(PY&B;:K\4C+.9T21XXJ9Z66+90%#PE6:IVU'0RG$QI' MUO=!]O/:6NR4&>#FXXT6.D8MK&5.)@Y*'1+YYJL<)_WNK'%J-(V!ZT3X^GWW MN^UBRJV7YD^26@+5W#HW'&R"J$$(B<],&5+IQFPZ:+0(IFVWF-?0LTTP5YY) MG5,\&SQ9$S-0$_2;X M.IZK1N36-@[ M,F!BWL9%<<>EVM*_\RC;1=/?_*/V_ ]02P,$% @ G()J4PML3/( UQX[L4."_W^,0;P1"#WJ[*5Z%@#K^ M/O[Z^3@F=G+U895P\@1*,RDZ7MAH>@1$)&,F9AUOH7VJ(\8\HC,J8LJE@(ZW M!NU]>/_ZU=5WOD^N;_L/Q"?S+$MU.PB6RV4CGC*A)5]D&%(W(ID$Q/=M_=[X M$_EUTUR;#($#U4 2JC-0Y.<%XW&[U6R%S8M6V&AMRQ10$X_$-(,V"<,@; :F M)GG7/K_ %QG)L8]>?V*X!\F4NB\M..9=!39 M6$T4;T@U0[?-L\"*O&W-:D^T/,LEX>7E99 ?+=?7K*HV-A &O]_?C:(Y)-1' M" @MVFD*W<39W^IM<^?!YJ"MKUE;YY'N9)3G_HAND8,US'^^K>:;(C]L^6=A M8Z5C[[UII0J'#TBRVO?84%) *L,1 RQ#6,Z\,WZ_'Y#MAB^,BKEP)[! M.38-46,FGX(8F&FQ:;Z8!#7]9EA >X-%GWL2IX[N1&>*1EDY%=R,&JEL(:<3 MX!VO0A3\^[:ZF(+8I.&6T]FQMG9$95O;$+LJ*H6D*K+A\.L>P?)Y4-0(4JHP MGA_-<7F M&$Q!*8CO-MT^Z#*WB'.IAKSF-X&T&9\][(>BO(\GP>H76!\+ZX"XOM .&+;P MSAR#9^>9,2;S6&9E37U1E7U:0N>.$AH .L8?@_@:KYQ.1;4CKC^S'<,6WH5C M\#:SQ1!FS'179 \T.9I=M;:^Z*K]6G+OG"2'"PBI4JGR!(\PS]"3"YSZUST9 MGPCR"Z'JSO4+]BWFGYS$?,LX/"R2":C3F&[KZ@YPVZNE=>DDK3%=]6-,!INR MS8+V)>@.!JD[QX/&"ZAG32>A=N,84ZV+#UQ?0W@:T,H =8=9:=J"#/\G(%M? M"[+E(LC6/R#=7-$7?>GAUT#$=@[OFV1-^Z3'0@=4;Y'RP]?1U2'<$1FCNN+4O7]G3,#--50$^A M5];4EU?9IR7DVL:-N5?&!W,I3EP7[NOJ2VK?JZ7EVF;-;^@R ]&32;(0Q;)( M'XOL@+B^W X8MO!?:L6,P>/(52GKBZW*K67FVD;,0($9 M?H!75/D=%G/O6SU.I\=/E,]%J"_#YUP7+-^ZMO^RTZ>^U@M07T^T(HXS7"N\ M6[JN;QHJ:)_9&ZV0BC_X9W!'5 ME]..40O)M;T5.]QN5M&'94OP/MEJN M@KV\W&&!>:1Z<\2\F0>$L>0O4$L! A0#% @ G()J4\IU7'R!$0 AFH M X ( ! &0R-#$S-3)D.&LN:'1M4$L! A0#% @ MG()J4S\WIVY'#P NRP !$ ( !K1$ &0R-#$S-3)D97@Y M.3$N:'1M4$L! A0#% @ G()J4TV1Y.I, P @0L !$ M ( !(R$ &]R:6,M,C R,3$Q,#DN>'-D4$L! A0#% @ G()J4R(]+U.Q M!@ .TH !4 ( !GB0 &]R:6,M,C R,3$Q,#E?;&%B+GAM M;%!+ 0(4 Q0 ( )R":E,+;'+,X00 )HN 5 " 8(K M !O